Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Gary Fanger"'
Publikováno v:
Translational Oncology, Vol 7, Iss 5, Pp 626-631 (2014)
In cancer chemotherapy, one axiom, which has practically solidified into dogma, is that acquired resistance to antitumor agents or regimens, nearly inevitable in all patients with metastatic disease, remains unalterable and irreversible, rendering th
Externí odkaz:
https://doaj.org/article/f8e08441e2d743a5ad8a85047bb16e92
Autor:
Jan Scicinski, George Fisher, Corey Carter, Cheryl Cho-Phan, Pamela Kunz, Shoucheng Ning, Susan Knox, Bryan Oronsky, Scott Caroen, Christopher Parker, Gary Fanger, Tony Reid
Publikováno v:
Redox Biology, Vol 5, Iss , Pp 422- (2015)
Background: RRx-001 is a novel NO and hypoxia mediated anticancer agent with epigenetic activity. In the first-in-human, Phase I trial, 5/5 patients who progressed on RRx-001 treatment were resensitized to previously refractory therapy, hinting at a
Externí odkaz:
https://doaj.org/article/ac42b765458d4bcfa7e40cd1563e5a81
Autor:
Bryan Oronsky, Gary Fanger, Susan J. Knox, Donna M. Peehl, Jan Scicinski, Michelle M. Kim, Shoucheng Ning, Peter Langecker
Publikováno v:
Redox Biology
The endogenous mediator of vasodilation, nitric oxide (NO), has been shown to be a potent radiosensitizer. However, the underlying mode of action for its role as a radiosensitizer – while not entirely understood – is believed to arise from increa
Autor:
Arnold L. Oronsky, Christopher A. Larson, Gary Fanger, Bryan Oronsky, Tony R. Reid, Jan Scicinski, Meaghan Stirn
Publikováno v:
Oncotarget
Oncolytic viruses have had a tumultuous course, from the initial anecdotal reports of patients having antineoplastic effects after natural viral infections a century ago to the development of current cutting-edge therapies in clinical trials. Adenovi
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry
Resistance to chemotherapy, biological and targeted therapies is an important clinical problem. Resistance can arise and/or be selected for multiple mechanisms of action. Unfortunately, acquired resistance to antitumor agents or regimens is nearly in
Autor:
Christopher W. Parker, Jan Scicinski, Gary Fanger, Scott Caroen, Bryan Oronsky, Michelle Lybeck, Neil Oronsky
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 14:1187-1198
As early as the 1920s, the eminent physician and chemist, Otto Warburg, nominated for a second Nobel Prize for his work on fermentation, observed that the core metabolic signature of cancer cells is a high glycolytic flux. Warburg averred that the pr
Publikováno v:
Translational Oncology
Tumors are spatially heterogeneous, with regions of relative hypoxia and normoxia. The tumor microenvironment is an important determinant of both tumor growth and response to a variety of cytotoxic and targeted therapies. In the tumor microenvironmen
Autor:
Jan Scicinski, Michelle M. Kim, William L. Fitch, Pedro Cabrales, Arnold L. Oronsky, Michael J Taylor, Christopher D. Lao, Ron Korn, Howard A. Burris, Jeffrey R. Infante, Shoucheng Ning, Tony R. Reid, Susan J. Knox, Bryan Oronsky, Gary Fanger, Corey A. Carter, Curt L Scribner, Nacer Abrouk, Donna M. Peehl, Meaghan Stirn
Publikováno v:
The Lancet. Oncology. 16(9)
Summary Background Epigenetic alterations have been strongly associated with tumour formation and resistance to chemotherapeutic drugs, and epigenetic modifications are an attractive target in cancer research. RRx-001 is activated by hypoxia and indu
Autor:
Cheryl D. Cho-Phan, Pamela L. Kunz, Bryan Oronsky, Corey A. Carter, Jan Scicinski, Christopher W. Parker, Scott Caroen, Gary Fanger, Shoucheng Ning, George A. Fisher, Tony R. Reid, Susan J. Knox
Publikováno v:
Redox Biology, Vol 5, Iss, Pp 422-(2015)
Background RRx-001 is a novel NO and hypoxia mediated anticancer agent with epigenetic activity. In the first-in-human, Phase I trial, 5/5 patients who progressed on RRx-001 treatment were resensitized to previously refractory therapy, hinting at a g
Autor:
Darrick, Carter, Davin C, Dillon, Lisa D, Reynolds, Marc W, Retter, Gary, Fanger, David A, Molesh, Paul R, Sleath, Patricia D, McNeill, Thomas S, Vedvick, Steven G, Reed, David H, Persing, Raymond L, Houghton
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(2)
Lipophilin B mRNA is overexpressed in approximately 70% of breast tumors and shows a high degree of correlation with the mRNA expression profile of mammaglobin. This is further supported by the recent finding that, like other members of the secretogl